| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Daxor schließt Kapitalerhöhung über 8,1 Mio. US-Dollar an der NASDAQ ab | 1 | Investing.com Deutsch | ||
| 23.01. | Daxor Corporation Announces $9 Million Registered Direct Offering | 1 | GlobeNewswire (USA) | ||
| 23.01. | DAXOR CORP - 8-K, Current Report | 2 | SEC Filings | ||
| 21.10.25 | Daxor Corporation: Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit | 2 | GlobeNewswire (USA) | ||
| 30.09.25 | Daxor Corporation: Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA | 252 | GlobeNewswire (Europe) | Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation... ► Artikel lesen | |
| DAXOR Aktie jetzt für 0€ handeln | |||||
| 23.09.25 | Daxor stellt auf Fachtagung neues, von der FDA zugelassenes Blutanalysegerät vor | 4 | Investing.com Deutsch | ||
| 23.09.25 | Daxor to showcase new FDA-cleared blood volume analyzer at HFSA meeting | 1 | Investing.com | ||
| 23.09.25 | Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting | 3 | GlobeNewswire (USA) | ||
| 07.08.25 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System | 207 | GlobeNewswire (Europe) | Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume... ► Artikel lesen | |
| 04.03.25 | Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 | 205 | GlobeNewswire (Europe) | Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the... ► Artikel lesen | |
| 04.03.25 | Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 | 207 | GlobeNewswire (Europe) | Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | Märkte am Morgen: Gold, Silber, Bitcoin, Amgen, Alphabet, AMD, SAP, Siemens Healthineers, BASF | Das Umfeld an den Aktienmärkten ist aktuell alles andere als einfach. Das hat sich gestern mal wieder deutlich gezeigt. Der DAX geriet nach guten Start unter Druck und schloss 0,72 Prozent tiefer bei... ► Artikel lesen | |
| THERMO FISHER | 460,70 | +0,35 % | Thermo Fisher to Close Franklin, Mass. Site, Cut Up to 80 Jobs | ||
| SERNOVA BIOTHERAPEUTICS | 0,086 | -7,53 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,400 | 0,00 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,670 | -2,20 % | GERATHERM MEDICAL AG - Schwäche im aktuellen Marktumfeld | ||
| INNOVAQOR | - | - | InnovaQor, Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| PLUS THERAPEUTICS | 0,256 | +10,65 % | Plus Therapeutics Inc.: Plus Therapeutics Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization | HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MEDICLIN | 3,860 | -1,03 % | EQS-News: MEDICLIN AG: Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Personalie
Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025
16.12.2025 / 15:00 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development | BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| CO-DIAGNOSTICS | 0,172 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.01.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 22.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.01.2026ISIN NameCA74290F1009 PROBE... ► Artikel lesen | |
| QUIDELORTHO | 24,800 | 0,00 % | QuidelOrtho Corp - 8-K, Current Report | ||
| VERU | 2,340 | +4,46 % | Veru Inc.: Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th |